Pentadecanoic Acid for Health & Longevity
Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / Grok 4
Also known as: C15:0, Pentadecylic Acid, Fatty15
Motivation
Pentadecanoic acid is a saturated fat with an odd number of carbons, found in small amounts in whole dairy fat. People with more of it in the blood tend to have less heart disease and type 2 diabetes, and laboratory work links it to cellular maintenance pathways shared with other longevity candidates. A purified supplement is a different question from a marker of dairy intake.
For years the molecule was mainly a way to measure dairy-fat intake, because the body makes little of it. Dolphin research, then cell and animal work, proposed that it is an essential fat the diet must supply. That claim is disputed. No deficiency disease is accepted for it, and much of the argument comes from investigators tied to a company that sells a supplement. Short human studies have tested a purified dose over a few months.
This review examines what pentadecanoic acid is, how it is thought to act, what human and population evidence exists for benefits and harms, and how supplementation has been given. It is for adults who already attend to diet, training, and measured risk, and who want the evidence separated from the marketing.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
High-level sources on pentadecanoic acid (C15:0, the 15-carbon odd-chain saturated fat), its dairy-fat origin, and the supplement claim.
Independent fatty-acid researcher Bill Harris and host Simon Hill examine the essential-fat claim, the two human trials, and where Fatty15 marketing runs ahead of the data.
- New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. - Ciesielski et al., 2024
Mini-review of metabolism and the disputed essential-fat claim, including how little fiber fermentation seems to raise blood levels.
- A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease. - Jenkins et al., 2015
Narrative review of how odd-chain fats are produced, absorbed, and used as markers of dairy intake in health studies.
- Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? - Venn-Watson et al., 2020
Primary paper behind the essential-fat hypothesis. Stephanie Venn-Watson co-founded Seraphina Therapeutics, which sells a C15:0 supplement (Fatty15).
No substantial discussion was found from Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension. A Huberman peptide episode uses “pentadecapeptide,” a different molecule. Lifespan.io hosts an 8 August 2024 press release rather than an independent review, so that page is not listed. FoundMyFitness has a one-minute abstract reprint and a members-only Q&A (#64) that asks whether pentadecanoic acid has health benefits among other topics; the answer is not public, so neither is listed as a high-level overview. Fewer than five sources met the bar for a high-level overview.
Grokipedia
Primary page on the molecule: structure, dairy-fat origin, use as an intake marker, and the contested essential-fat and cholesterol claims.
Examine
No dedicated Examine.com page for pentadecanoic acid was found. Site search returned no results. A research-feed study summary of one diet trial exists and is not a primary page for this intervention.
ConsumerLab
What is C15:0 fatty acid (found in fatty15), and does it have health benefits?
Public text names Fatty15 and says hair, skin, sleep, and aging claims lack trials. Further detail is membership-only.
Systematic Reviews
These reviews pool circulating pentadecanoic acid, mostly as a dairy-fat marker, not as a purified supplement.
- Lipid biomarkers for the prediction of type 2 diabetes risk, an umbrella review and updated meta-analyses of prospective observational studies. - Chen et al., 2026
Umbrella review of lipid markers. Pentadecanoic acid tracked with less type 2 diabetes (relative risk (RR; comparative chance) 0.82), not a supplement trial.
- Biomarkers of dairy fat intake, incident cardiovascular disease, and all-cause mortality: A cohort study, systematic review, and meta-analysis. - Trieu et al., 2021
Eighteen observational studies. Highest versus lowest levels: relative risk (RR; comparative chance) 0.88 for cardiovascular disease, and no lower mortality.
- Saturated fatty acid biomarkers and risk of cardiometabolic diseases: A meta-analysis of prospective studies. - Li et al., 2022
Prospective cohorts. Higher pentadecanoic acid tracked with less type 2 diabetes (RR 0.76 comparing extreme thirds).
- Biomarkers of dairy fat intake and risk of cardiovascular disease: A systematic review and meta analysis of prospective studies. - Liang et al., 2018
Thirteen cohorts of dairy-fat markers, not supplements. Pentadecanoic acid was null for total cardiovascular disease (RR 0.94) and lower for heart failure.
- Comprehensive Investigation on Associations between Dietary Intake and Blood Levels of Fatty Acids and Colorectal Cancer Risk. - Lu et al., 2023
Meta-analysis of blood fatty acids. Pentadecanoic acid was the marker tied to lower colorectal cancer risk, and the authors call that signal limited.
No systematic review of adverse effects from pentadecanoic acid supplements was found, so harm from supplementation is unrepresented here. The cardiovascular syntheses disagree on total cardiovascular disease because the later pool included more cohorts than the earlier null pool, and both agree these papers do not test a capsule.
Mechanism of Action
Pentadecanoic acid is a 15-carbon saturated fatty acid. Rumen microbes make most of what people eat, so butter and whole dairy fat are the main foods, with smaller amounts in some beef and fish. Humans build little of it. Gut microbes can turn fermentable fiber into propionate, and a fraction of that can be lengthened into odd-chain fat, but fiber-feeding studies show only a small or absent rise in blood levels (Ciesielski et al., 2024).
After absorption it is built into membrane phospholipids. A saturated tail is less prone to oxidative chain reactions than a polyunsaturated one. That membrane idea, sometimes called cellular fragility, is pressed by Stephanie Venn-Watson, who co-founded Seraphina Therapeutics, the company that sells Fatty15. The same group’s cell and animal work reports activation of AMP-activated protein kinase (AMPK, a sensor that shifts cells toward maintenance when fuel is low) and peroxisome proliferator-activated receptors alpha and delta (PPAR-α and PPAR-δ, regulators of fat use), and, in some assays, inhibition of mechanistic target of rapamycin (mTOR, a growth signal) (Venn-Watson et al., 2020; Venn-Watson & Schork, 2023).
Odd-chain breakdown yields propionyl-CoA (CoA, coenzyme A, a carrier for small carbon pieces), which can enter the citric-acid cycle (energy pathway) as succinyl-CoA, whereas even-chain fats yield acetyl-CoA. A human elimination half-life is not established. In rats one oral dose peaked near one hour and was still above baseline at 24 hours. In people, 200 mg daily raised the blood level over 12 weeks. It is not selective for one receptor.
Historical Context & Evolution
Pentadecanoic acid entered nutrition research as a marker, not a supplement. Rumen bacteria make odd-chain fats that people synthesize poorly, so the level in blood or adipose tissue has been used as a sign of dairy-fat intake (Jenkins et al., 2015). Cohorts then found that higher marker levels lined up with somewhat lower rates of type 2 diabetes and cardiovascular disease, which did not match treating every saturated fat as the same exposure.
The jump from marker to candidate nutrient came from marine-mammal work. Veterinarian Stephanie Venn-Watson, studying aging bottlenose dolphins, reported that animals with higher levels looked metabolically healthier, then tested the pure fatty acid in cells and rodents. A 2020 paper from that group argued the pattern resembled an essential fatty acid: low intake tracked with worse metabolic markers, and restoring it had biological activity (Venn-Watson et al., 2020). She co-founded Seraphina Therapeutics to sell it as Fatty15.
Independent reading has not closed the question. A 2024 mini-review calls essentiality controversial: the marker studies were not supplementation trials, endogenous production has not been ruled out, and no deficiency syndrome is accepted the way linoleic-acid deficiency is (Ciesielski et al., 2024). What changed is the granularity of the saturated-fat debate. Even-chain fats such as palmitic acid and odd-chain fats such as pentadecanoic acid do not look interchangeable in observational data. That is a reason to study the molecule. It is not a finding that a capsule reproduces the dairy-marker associations, and it is not a final word.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the supplementation record is two small 12-week trials, and the cardiovascular and diabetes findings are observational biomarker studies rather than replicated trials of the supplement.
Medium 🟩 🟩
Type 2 Diabetes Association
Higher blood pentadecanoic acid is associated with a lower chance of later type 2 diabetes in prospective syntheses of saturated-fat biomarkers (Li et al., 2022). The same marker problem applies: people who eat more ruminant fat differ in many other ways. No randomized controlled trial (RCT; a trial that assigns people at random to the fat or a control) has tested whether giving the fatty acid prevents diabetes. Glucose and insulin did not separate from placebo over 12 weeks in young adults with overweight (Robinson et al., 2024).
Magnitude: Extreme thirds of circulating pentadecanoic acid were associated with an RR of 0.76 (95% confidence interval (CI; the plausible range) 0.63 to 0.91) for incident type 2 diabetes. Supplementation trials have not reported a diabetes-incidence figure.
Low-Density Lipoprotein Cholesterol with Diet
In women with fatty liver, 300 mg/day for 12 weeks added to an Asian-adapted Mediterranean-style diet lowered low-density lipoprotein (LDL; the cholesterol fraction most tied to artery disease) cholesterol further than that diet alone (Chooi et al., 2024). The trial was randomized. A corporate laboratory (WIL@NUS) is among the affiliations. Weight, liver fat, and several other markers improved on the diet with or without the fatty acid. This is one trial of a validated cholesterol surrogate, not a cardiovascular-event result.
Magnitude: LDL cholesterol fell further with 300 mg/day plus diet than with diet alone over 12 weeks in women with fatty liver. The published abstract does not state that extra drop in concentration units.
Low 🟩
Cardiovascular Disease Association ⚠️ Conflicted
Higher pentadecanoic acid, a dairy-fat marker, tracked with less cardiovascular disease in one cohort pool (Trieu et al., 2021) and not in an earlier one (Liang et al., 2018). No capsule trial measured heart attack or stroke. The net reading is a marker link, not proof a capsule prevents events.
Magnitude: Highest versus lowest levels were associated with an RR of 0.88 (CI 0.78 to 0.99) for total cardiovascular disease across 18 observational studies. The 2018 pool’s RR for total cardiovascular disease was 0.94 (CI 0.77 to 1.15).
Liver Enzymes
200 mg/day for 12 weeks lowered gamma-glutamyl transferase (GGT, a liver enzyme) versus placebo. Alanine aminotransferase (ALT, a liver enzyme) and aspartate aminotransferase (AST, a liver enzyme) did not. A later split above 5 micrograms per milliliter included placebo and was chosen afterward (Robinson et al., 2024).
Magnitude: GGT was a mean 11 U/L lower versus placebo. In the later split, median ALT change was −29 U/L above the line, +6 U/L in other treated people, and 0 on placebo; AST change was −6, +3, and 0 U/L.
Hemoglobin above a Blood-Level Line
The same later split found a hemoglobin rise above 5 micrograms per milliliter. That contrast included other treated people and placebo, not treated people alone. The main trial result was a higher blood level of the fat (Robinson et al., 2024).
Magnitude: Median hemoglobin change was +0.60 g/dL above the line, −0.40 g/dL in treated people below it, and −0.50 g/dL on placebo. The +0.60 figure is that group’s change, not the gap versus the others.
Colorectal Cancer Association
A fatty-acid meta-analysis found higher blood pentadecanoic acid tracked with less colorectal cancer, unlike the other blood fats in that pool. The authors say the studies are too few for a firm conclusion. No capsule trial has measured cancer (Lu et al., 2023).
Magnitude: Higher versus lower blood pentadecanoic acid was associated with an RR of 0.60 (CI 0.44 to 0.82) for colorectal cancer, from two articles in that pool.
Speculative 🟨
Cell-Panel Overlap with Rapamycin
Human cell panels found dose-dependent activity that overlapped rapamycin, including inflammatory readouts (Venn-Watson & Schork, 2023). No human study has shown slower aging, so the basis is in-vitro only.
Bifidobacterium Abundance ⭕️ Not Central to Health & Longevity
The fatty-liver diet trial reported more Bifidobacterium adolescentis when pentadecanoic acid was added (Chooi et al., 2024). That is one gut species, not a symptom or disease event. The basis is a microbial count only.
Sleep, Skin, and Hair Claims
Marketing for oral products names deeper sleep and healthier skin and hair. No controlled trials exist, so the basis is anecdotal promotion only.
Benefit-Modifying Factors
- Baseline blood level: ALT, AST, and hemoglobin moved only above about 5 micrograms per milliliter. The whole-group GGT drop did not depend on that line. People already near it may have less room to move.
- Dairy intake: Whole dairy fat is the usual food source. High habitual intake can raise the baseline and shrink the apparent effect of a capsule.
- Sex: The LDL finding is from a trial in women. Men do not have a parallel supplementation trial, so the cholesterol signal is untested in men.
- Liver fat and body weight: Enzyme changes were explored in young adults with overweight. LDL was explored in women with fatty liver on a structured diet.
- Age: Published supplementation trials are not in older adults. A longevity-oriented response at age 55 and above is unmeasured.
- Genetics: No common gene variant is known to enlarge or shrink the benefit. Rare defects in vitamin B12-dependent propionate handling could theoretically change odd-chain disposal.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: adverse-event reports from human trials cover about 12 weeks and do not show a replicated clinical harm.
Medium 🟥 🟥
No risk reaches Medium: there is no single trial, and no consistent observational series, showing a symptomatic or validated-surrogate harm from pentadecanoic acid.
Low 🟥
Speculative 🟨
Effects beyond 12 Weeks
Human use of about 12 weeks showed no serious adverse events, and short rat studies showed no toxicity. No controlled long-term data exist, so the basis is mechanistic extrapolation only.
Risk-Modifying Factors
- Baseline level: People who already sit above 5 micrograms per milliliter were not the subgroup in which after-the-fact lab shifts were described. Their margin for change is unknown.
- Sex: Safety counts mix a women-only diet trial and a young-adult trial. A sex difference in adverse events is not established.
- Pre-existing liver disease: Enzyme monitoring matters most where ALT or AST is already high. The young-adult trial started from that setting.
- Fat absorption: Conditions that block fat uptake can blunt the rise in blood level. That changes exposure, not a known toxic pathway.
- Age: Adults 55 and older are outside the published trials. The adverse-event pattern at older ages is unmeasured.
- Genetics: No common variant is known to increase harm. Rare B12-pathway defects are a theoretical modifier, not a documented risk group.
Key Interactions & Contraindications
- Statins (cholesterol-lowering drugs; atorvastatin, rosuvastatin): No interaction study exists (monitor). Both can lower LDL cholesterol, so the combined change is unquantified. A lipid panel at 12 weeks shows the joint result.
- Omega-3 fatty-acid supplements: Often used for the same lipid goals. No study shows additivity or antagonism (monitor). One does not stand in for the other.
- Other prescription and over-the-counter drugs: No studied class interaction at 200–300 mg for 12 weeks (monitor). The clinical consequence is an unmeasured combined effect, not a documented reaction.
- Pregnancy and lactation: Pregnant participants were excluded from the human trials (caution). Fetal exposure is unstudied. The mitigating step used in trial design was exclusion.
Populations who should avoid Pentadecanoic Acid:
- None identified
Risk Mitigation Strategies
- Studied window: Trials used about 200–300 mg/day for 12 weeks and did not report serious adverse events. Use past that window is the untested risk.
- Lab check at 12 weeks: ALT, AST, and LDL cholesterol at the trial horizon would show an unexpected enzyme or lipid change before use runs longer.
- No higher unstudied dose: Doses above the 300 mg trial dose have no human adverse-event record, which is the same untested-harm problem.
Therapeutic Protocol
- Whole-dairy fat: Odd-chain fat is about 1–3% of dairy fat. This is the exposure behind the biomarker studies. It is not a measured 200 mg dose.
- 200 mg each morning: The University of California San Diego young-adult trial led by Schwimmer used oral free fatty acid at this dose for 12 weeks (Robinson et al., 2024).
- 300 mg once daily with a meal: The TANGO trial put 300 mg in soymilk beside an Asian-adapted Mediterranean-style diet (Chooi et al., 2024).
- Commercial 100 mg: Fatty15 (Seraphina Therapeutics, Venn-Watson) suggests 100 mg daily, below both trial doses and not compared with them.
- Time of day: Trial dosing was morning or with the first meal. A superior clock time has not been tested.
- Half-life: Human elimination half-life is not established. Rats peaked near 1 hour and stayed above baseline at 24 hours.
- Single versus split: Trials used one daily dose. Splitting has not been compared.
- Genetics: No common variant has a dose rule. Rare B12-dependent propionate defects are a theoretical caveat only.
- Sex: The LDL result is from women. No sex-specific dose has been defined.
- Age: Published trials enrolled young adults. A pending trial at age 55 and older still uses 200 or 300 mg.
- Baseline level: About 200 mg raised the blood level by roughly 1.9 micrograms per milliliter over 12 weeks. A higher start leaves less room.
- Health context: Enzyme questions were studied in overweight young adults; LDL was studied in women with fatty liver on a diet. Neither sets another dose.
Discontinuation & Cycling
- Duration: Published use is 12 weeks, not lifelong. Nothing in the trials establishes a required stop date.
- Withdrawal: No withdrawal syndrome was reported after 12 weeks. A fatty acid is not a receptor-blocking drug.
- Taper: No taper was used in the trials. Stopping was a simple halt of the daily dose.
- Cycling: Cycling was not studied. The trials gave the dose every day for the full 12 weeks.
Sourcing and Quality
- Chemical form: Trials used the free fatty acid, not a triglyceride bound in dairy. Labels name pentadecanoic acid or C15:0.
- Identity testing: A third-party assay of C15:0 content, and a low share of even-chain fats, is the relevant purity check.
- Named product: Fatty15 (Seraphina Therapeutics) is the commercial capsule discussed in public trial commentary. The journal abstract of the young-adult trial describes a pure free fatty acid without a brand (Robinson et al., 2024).
- Regulatory frame: Sold as a dietary supplement, not an approved drug. Flavor listing FEMA 4334 (Flavor and Extract Manufacturers Association) is not a disease approval.
Practical Considerations
- Time to effect: Blood levels rise over 12 weeks. Lab shifts, where reported, were also read at 12 weeks, often only in an after-the-fact subset.
- Common pitfall: Treating a dairy-marker association as proof that a capsule prevents heart disease or diabetes.
- Second pitfall: Expecting liver-fat loss from the capsule. In the diet trial, liver fat tracked the diet.
- Regulatory status: Sold as a supplement in the United States. It is not an approved drug, and flavor-use listing is not a health claim.
- Cost and access: Branded capsules cost more than the trace in dairy fat. Insurers and public health systems do not pay for either, so coverage does not steer the research.
Interaction with Foundational Habits
- Sleep: Direction none demonstrated. Marketing claims deeper sleep. Human trials have not shown better or worse sleep. A pending older-adult trial plans a sleep questionnaire.
- Nutrition: Direction indirect. Food source is whole dairy fat (about 1–3% of that fat). Fiber-to-propionate conversion may add a little, but feeding studies show a small or absent blood-level rise. The capsule does not replace overall diet quality.
- Exercise: Direction none demonstrated. No trial has tested training, hypertrophy, or dose timing around workouts. Nothing in the mechanism predicts blunting of training.
- Stress management: Direction none demonstrated. No human study has measured cortisol or a stress outcome. Cell anti-inflammatory readouts are not a stress effect.
Monitoring Protocol & Defining Success
Before oral pentadecanoic acid, a baseline draw records the person’s circulating level, liver enzymes including gamma-glutamyl transferase, LDL cholesterol, hemoglobin, and fasting glucose. The fatty acid is not on a routine panel, and no independent reference interval exists. The 5 microgram per milliliter line used in one trial comes from the same research circle that sells a supplement, so the comparison that matters is change from that person’s baseline. People who already eat a lot of whole dairy fat may start higher.
Ongoing labs repeat at 12 weeks, the length of the published trials, then every 6–12 months if use continues. Twelve weeks is when blood levels have been shown to rise and when cholesterol or enzyme changes in those trials were read. Later checks look for drift rather than a new acute effect.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Circulating pentadecanoic acid | No established target; track change from the person’s own baseline | Shows whether the dose raised the level the trials actually moved | Not a routine panel. A trial-used line of >5 micrograms per milliliter (about 20 micromoles per liter) is a research threshold, not a validated range. Fasting morning draw. |
| LDL cholesterol | <100 mg/dL; <70 mg/dL when artery disease is already a personal priority | The one supplement signal that is a validated cardiovascular surrogate | Conventional laboratory “desirable” is often <100 mg/dL, sometimes flagged only above 130. Fasting preferred. |
| ALT | <25 U/L in women; <33 U/L in men | Liver-enzyme signal was after-the-fact and only above a blood-level line | Many laboratories use an upper limit near 33–45 U/L. Fasting not required. Pair with AST. |
| AST | <30 U/L | Second liver enzyme in the same after-the-fact split | Conventional upper limits are often near 35–40 U/L. Interpret with ALT, not alone. |
| GGT | <20 U/L | The liver enzyme that fell versus placebo at 12 weeks | Conventional upper limits are often near 30–50 U/L. The young-adult trial’s reference was <36 U/L. Fasting not required. Pair with ALT and AST. GGT is gamma-glutamyl transferase. |
| Hemoglobin | Women 12.5–14.5 g/dL; men 14.0–15.5 g/dL | An after-the-fact rise was reported above the 5 microgram line | Conventional intervals are wider (women often 12.0–15.5; men 13.5–17.5). Not a reason to chase high values. |
| Fasting glucose | 75–90 mg/dL | Cohorts link the biomarker to diabetes; trials did not move glucose clearly | Conventional fasting interval is about 70–99 mg/dL. True fasting, morning. |
| hs-CRP | <1.0 mg/L | Cell work is anti-inflammatory; human trials have not shown a CRP drop | Conventional cardiovascular cut-points often use <1, 1–3, and >3 mg/L. Skip during an obvious infection. hs-CRP is high-sensitivity C-reactive protein, a low-grade inflammation marker. |
Qualitative markers, recorded at baseline and at each lab visit:
- Energy: ordinary daytime energy, without expecting a stimulant-like change.
- Sleep quality: continuity and feeling restored. Claims exist; trials have not established an effect.
- Gastrointestinal comfort: nausea, loose stools, or fullness after the oral capsule, versus the person’s baseline.
- Training tolerance: recovery from usual exercise. No trial has tested an exercise interaction.
Emerging Research
- Older-adult red-cell trial: NCT07812792 (ReCellience15, Inc., an industry sponsor) is not yet recruiting. It plans 93 adults aged 55 and older, 200 mg, 300 mg, or placebo for 12 weeks, with red-cell distribution width as the primary measure. A null result would weaken the red-cell and aging claim; a clear result would strengthen it.
- Essential-fat challenge: An independent mini-review treats essentiality as unresolved (Ciesielski et al., 2024). If ordinary diets and limited endogenous synthesis prove adequate, the case for a supplement as a missing nutrient weakens.
- Events versus markers: The largest cardiovascular synthesis measured blood levels, not capsules, and did not lower mortality (Trieu et al., 2021). No registered trial is testing heart attack, stroke, or diabetes onset. That gap can either confirm or erase the marker signal.
Conclusion
Pentadecanoic acid is a saturated fat with an odd number of carbons, found in whole dairy fat. Higher blood levels, a sign of dairy-fat intake, line up with a modestly lower chance of heart disease and type 2 diabetes in pooled studies. Those links are worth taking seriously, and too mixed in with the rest of the diet to show that this one fat is the protective piece.
Giving the purified fat has been tested in two short studies: young adults with extra body weight, and women with fatty liver on a Mediterranean-style diet. In the women’s study, the cholesterol fraction tied to artery disease fell further when the fat was added. One liver enzyme fell in the whole group against an inactive comparison. Other liver-enzyme and red-cell changes appeared only in a later split, among people above a proposed blood level. Liver fat followed the diet. No serious harms were reported over three months. That is not a heart attack, new diabetes, or a longer life.
The laboratory case, and the claim that the fat is essential, comes from Stephanie Venn-Watson, who co-founded a company that sells it. An independent short review treats that claim as unsettled. Insurers and public health systems do not pay for the capsule or for dairy fat, so payment does not shape this evidence. For a longevity-oriented adult, the picture is a dietary fat with a favorable shadow in population studies, a narrow capsule record, and no shown effect on lifespan.